The use of weight loss drugs is a fascinating area in the field of obesity management, particularly for individuals with Prader-Willi Syndrome (PWS). Some individuals with PWS have already been prescribed weight loss medications based on their specific medical needs and under the guidance of their healthcare teams. However, the general use of these drugs for PWS is still under investigation.
Numerous studies are being conducted worldwide to explore the effectiveness of weight loss drugs for individuals with PWS.
During the second PWS Stronger Together webinar, it was announced that an application had been submitted for funding a trial of Semaglutide (commercially known as Ozempic) for individuals with PWS. You can watch the webinar and learn more at www.pwsstrongertogether.co.uk/webinars
There are however a number of different types of weight loss drug, and studies are also being conducted to test how individuals with PWS tolerate them. For instance, a study is expected to take place this year in Australia to test Tirzepatide (also known as Mounjaro) which you can read about here- https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12625000147482 Additionally, a Phase 2 trial is anticipated to begin soon in the USA to test Setmelanotide (also known as Imcivree) and further information can be found at https://praderwillinews.com/news/phase-2-trial-test-setmelanotide-pws-begin-soon
Ozempic, Mounjaro, Imcivree, and other drugs all work in slightly different ways and are prescribed based on the needs of each individual patient. It is also important to remember that the digestive system of individuals with PWS functions differently from that of typical subjects. Therefore, whilst it is natural to hope for quick answers, thorough research into how these drugs are tolerated by people with PWS is vital.
We will keep you posted as soon as we know any more developments, so make sure you follow us on social media, check out our WhatsApp channel and subscribe to our newsletter at https://link.fpwr.org.uk/news